Emerging Treatments in HIV

Latest News

Improved Cognition Linked to Changes in Microbiota After Fecal Transplant in Hepatic Encephalopathy

By

Sweta Gupta

Beneficial changes in microbial composition and functionality with capsular fecal microbiota transplant lead to improved cognition in patients with cirrhosis and recurrent hepatic encephalopathy, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts. In order to determine…

Onchocerciasis Treatment With Ivermectin: Results Support Semiannual Mass Drug Administration

By

Sweta Gupta

While ivermectin plus albendazole was not superior in the treatment of onchocerciasis compared with ivermectin alone, semiannual treatment with or without albendazole was superior to annual treatment for suppressing microfilaria in the skin.

FDA Panel Votes on Treatment for Extensively Drug Resistant, Multidrug Resistant TB

By

Diana Ernst, RPh

The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.

Ceftolozane/Tazobactam Approved for Hospital-Acquired Bacterial Pneumonia

Zerbaxa has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Fofomycin Injection: New Drug Application for Treatment of Complicated UTI

By

Haymarket Media

Contepo, an investigational epoxide intravenous (IV) antibiotic, has broad spectrum activity against Gram-negative and Gram-positive pathogens, including multi-drug resistant strains such as ESBL-producing Enterobacteriaceae.

TOL-463 Effective for Bacterial Vaginosis and Vulvovaginal Candidiasis

By

Infectious Disease Advisor Contributing Writer

TOL-463, particularly in vaginal insert form, is effective and safe in treating bacterial vaginosis and vulvovaginal candidiasis.

Ampicillin Plus Ceftriaxone: An Effective Alternative for E faecalis Infective Endocarditis

By

Bradley van Paridon

Ampicillin plus ceftriaxone was an effective treatment for penicillin-susceptible Enterococcus faecalis infective endocarditis compared with ampicillin plus gentamicin.

Continuous Antibiotic Infusion via Elastomeric Pumps Safe and Effective in Outpatients

By

Bradley van Paridon

Treating outpatients with continuous infusions of flucloxacillin, cefepime, vancomycin, and piperacillin/tazobactam using elastomeric pumps was effective and safe.

Could Zika Virus Be a Potential Treatment for Neuroblastoma?

By

Steve Duffy

Even with intensive therapy, survival among neuroblastoma patients is poor, indicating a need for alternative treatments.

Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis

By

Diana Ernst, RPh

Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.

TPOXX Approved for the Treatment of Human Smallpox Disease

By

Haymarket Media

The approval was supported by findings from 12 clinical trials of TPOXX with more than 700 healthy volunteers that showed no drug-related serious adverse events.

Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen

By

Haymarket Media

Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.

Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV

By

Crystal Wong, MD

Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.

FDA Green Lights Odefsey for Treating HIV-1

By

Colleen Hall

Combining emtricitabine and tenofovir alafenamide (Gilead Sciences) and rilpivirine (Janssen Sciences), Odefsey is Gilead’s second tenofovir alafenamide-based regimen to receive FDA approval.

Drop-to-Drop Variation Noted With Fingerprick Blood

Authors say variation in blood analytes holds implications for point-of-care testing.

Combination HIV Antiretroviral Promising To Rid Body of HIV For Months

By

Haymarket Media

The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.

Rifamycin-ART, Other Medication Dosing Errors Noted With TB Therapy

More than half of study patients had at least one medication error linked to antituberculosis therapy.

FDA Approves Label Changes For Olysio Use in HIV Co-Infection, HCV Genotype 4

By

Haymarket Media

The Food and Drug Administration (FDA) has approved label changes for simeprevir; (Olysio, Janssen) to include dosing recommendations for the treatment of hepatitis C virus (HCV)/HIV-1 co-infection.

New HIV Combination Medication Meets Primary Objective

By

Lea Eslava-Kim, PharmD

Gilead announced that phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for the treatment of HIV-1 infection met its primary objective.

Genes May Hold The Key To A Better HIV Vaccine

Findings challenge one-shot-fits-all approach, could guide development of future vaccines.